230 PARK AVENUE, NEW YORK, NY
Market cap: $391.2M (9/15/2025)
Price: $8.61
News, Articles of Incorporation, Bylaws
Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
Agrees to Acquire Y-mAbs Therapeutics
Shareholder votes
Annual Report to Security Holders
Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
Reports First Quarter 2025 Financial Results and Recent Corporate Developments
News, Underwriting Agreement, Legal Opinion
Q2
Q1
Amended Annual Report
FY 2024
Q3
FY 2023
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Solicitation/Recommendation Statement
Tender Offer Statement by Third Party
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Tender Offer Statement by Issuer
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS
Post-Effective Amendment to Registration Statement
Amended Schedule 14D-9 Solicitation/Recommendation Statement
Amended Tender Offer Statement by Third Party